Boehringer Mannheim Corporation Enrolls First Patient in Phase III Program for New Once-Daily Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).